Somatostatin receptor scintigraphy in metastatic breast cancer patients

Oncology Reports

Volumn 13, Issue 1, 2005, Pages 31-35

  Mezi, Silvia ^a   Primi, Francesca ^a   Orsi, Errico ^b   Capoccetti, Francesca ^c   Scopinaro, Francesco ^a   Schillaci, Orazio ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Metastatic breast cancer; Octreotide; Somatostatin; Somatostatin receptor scintigraphy

Indexed keywords

DIAGNOSTIC AGENT; DRUG DERIVATIVE; PENTETREOTIDE; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE TUMOR; BREAST TUMOR; EVALUATION; FEMALE; HUMAN; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 21644437926     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.13.1.31     Document Type: Article

References (24)

1. Reisine T and Bell Gl: Molecular biology of somatostatin receptors. Endocr Rev 16: 427-442, 1995.
2. Wang CH, Tang CW, Liu CL and Tang LP: Inhibitory effect of octrotide on gastric cancer growth via MAPK pathway. World J Gastroenterol 9: 1904-1908, 2003. (Pubitemid 37168410)
3. Florio T, Thellung S, Arena S, Corsaro A, Bajetto A, Scettini G and Stork PJ: Somatostatin receptor 1 (SSTR-1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol Paris 94: 239-250, 2000.
4. Boccardo F and Amoroso D: Management of breast cancer: Is there a role for somatostatin and its analogs? Chemotherapy 47 (suppl 2): 62-77, 2001.
5. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carrol AM, Bell GI, Shally AV, Vaysse N and Susini C: Inhibition of cell proliferation by the Somatostatin analogue RC-160 is mediated by Somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580-1584, 1995.
6. ++ and interference with distal secretory events. Metabolism 39 (suppl 1): 101-104, 1990.
7. Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clere P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N and Susini C: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogs: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91: 2315-2319, 1994. (Pubitemid 24092094)
8. Klarlund JK: Tranformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 41: 707-717, 1985.
9. Ikeda SR and Schofield GG: Somatostatin blocks a calcium current in rat sympathetic ganglion neurones. J Physiol 409: 221-240, 1989. (Pubitemid 19052981)
10. Schombrunn A: Somatostatin action in pituitary cells involves two independent transduction mechanisms. Metabolism 39 (suppl 1):96-100, 1990.
11. + channel by insulin and somatostatin in guinea-pig pancreatic acinar cells. Jpn J Physiol 51: 355-363, 2001.
12. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J and Klijn JC: Prognostic value of receptors for insuline like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49: 7002-7009, 1989. (Pubitemid 20016583)
13. Sharma K and Srikant CB: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer 13 76: 259-266, 1998. (Pubitemid 28180381)
14. 1-Octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J Clin Oncol 18: 1331-1336, 2000.
15. Katzenellembogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Kent-Osborne C, Piwnicka-Worms D, Reba RC, Siegel BA, Welk MG and Shtern F: Tumor receptor imaging: proceedings of the National Cancer Institute Workshop, review of current work, and perspective for further investigations. Clin Cancer Res 1: 921-932, 1995.
16. Valkema R, Steens J, Cleton FJ and Pauwels EK: The diagnostic utility of somatostatin receptor scintigraphy in oncology. J Cancer Res Clin Oncol 122: 513-532, 1996. (Pubitemid 26284552)
17. 111In- DTPA-octreotide: a preliminary study. Nucl Med Comm 14: 962-968, 1993.
18. Schultz S, Hehnotz T, Schmitt J, Franke K, Otto HJ and Weise W: True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of ssUA and sst5. Breast Cancer Res Treat 72: 221-226, 2002. (Pubitemid 34430003)
19. Xu Y, Song J, Berelowitz M and Bruno JF: Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 137: 5634-5640, 1996. (Pubitemid 26423134)
20. Setyono-Han B, Henkelman MS, Foekens JA and Klijn GM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 15: 1566-1570, 1987. (Pubitemid 17044484)
21. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J and Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50: 254-251, 1991.
22. Denzler B and Reubi JC: Expression of somatostatin receptor in peritumoral veins of human tumors. Cancer 85: 188-198, 1999. (Pubitemid 29031374)
23. Ingle JN, Suman VJ, Kardinal CG, Krook JE, Mailliard JA, Veeder MH, Loprinzi CL, Dalton RJ, Hartmann LC, Conover CA and Pollak MN: A randomised trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85: 1284-1292, 1999. (Pubitemid 29125081)
24. Pollak M: Enhancement of antineoplastic effects of tamoxifen by somatostatin analogues. Digestion 57: 29-33, 1996.